New drugs: Ustekinumab, tocilizumab, and telavancin hydrochloride.
McCluggage
Lauren K
LK
Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, USA.
Hussar
Daniel A
DA
D000617:Aminoglycosides / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology; D002986:Clinical Trials as Topic; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D000077427:Lipoglycopeptides; D011565:Psoriasis / Q000188:drug therapy / Q000276:immunology; D016896:Treatment Outcome; D000069549:Ustekinumab
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000077427:Lipoglycopeptides; D000069549:Ustekinumab; C502936:tocilizumab; C487637:telavancin